{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "KMTS",
  "name": "Kestra Medical Technologies, Ltd.",
  "url": "https://frontierpicks.com/dossiers/KMTS/",
  "json_url": "https://frontierpicks.com/dossiers/KMTS.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "WCD share-capture story intact on fundamentals — FY26 revenue $95.1M (+59%), fiscal Q4 gross margin 54.8% — but the bid has thinned: the close was $25.64 on 2026-08-28, 9.6% under the $28.35 52-week high, with RSI(14) at 13.5 against 67.8 on 2026-08-21 and no dated news in between. The 2026-09-14 Q1 FY27 print is the first test of the $137M FY27 guide (+44%, a deceleration).",
  "invalidation_trigger": "A weekly close below $24 marks the post-guidance advance as failed, roughly 15% under the $28.35 52-week high. Secondary: the 2026-09-14 Q1 FY27 print comes and goes with the $137M guide reiterated rather than raised and ASSURE prescription growth well under the +63% YoY of fiscal Q4.",
  "catalyst_date": "2026-09-14",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-09-11",
  "invalidation_fired": true,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Fiscal year ends April 30. 'FY27' covers May 2026-April 2027; quarterly results have landed in September, December, March and July.",
    "58,602,497 common shares outstanding as of 2026-07-09 per the FY26 annual report cover page.",
    "Essentially all revenue derives from the ASSURE WCD system and its associated monitoring service - single-product concentration.",
    "Several executives sell under pre-adopted 10b5-1 plans; the July-August 2026 Form 4/144 flow is scheduled rather than discretionary.",
    "Bain Capital is the largest holder at roughly 46% of shares outstanding per August 2026 ownership tallies.",
    "The 2026-09-14 earnings date comes from third-party calendars; the company had not issued its own scheduling release as of 2026-08-30."
  ],
  "body_markdown": "## Current Thesis\n\nKestra Medical Technologies’ wearable-defibrillator share-capture thesis has lost its published price support; the 2026-09-14 results test whether operating growth still supports the business case. The 2026-09-11 adjusted close of $22.85 breached the $24 weekly-close condition published on 2026-08-30. That invalidation has occurred before earnings.\n\nFor the previously published advance, the narrative is dead — the week ended 2026-09-11 closed below its stated thesis-break level. This is an assessment of the price structure, not evidence that product demand has collapsed. Kestra’s 2026-07-14 release attributed revenue growth to market-share gains and expansion of the wearable cardioverter defibrillator (WCD) market. [Company results](https://investors.kestramedical.com/news-releases/news-release-details/kestra-medical-technologies-reports-fourth-quarter-and-fiscal-0).\n\nThe earnings date is now company-confirmed: Kestra announced on 2026-08-31 that fiscal first-quarter results would arrive after the market closes on 2026-09-14. The earlier calendar uncertainty is resolved. [Scheduling announcement](https://investors.kestramedical.com/news-releases/news-release-details/kestra-medical-technologies-report-first-quarter-fiscal-2027).\n\n## Bull Case\n\n- **Prescription demand supports reported growth.** For the quarter ended 2026-04-30, Kestra reported 6,357 ASSURE prescriptions, up 63% year over year, and revenue of $28.6 million, up 66%, in its 2026-07-14 release.\n- **Gross margin improvement is measured.** Fiscal fourth-quarter gross margin reached 54.8%, versus 44.3% a year earlier, according to the 2026-07-14 results.\n- **Annual guidance still implies expansion.** On 2026-07-14, management guided fiscal 2027 revenue to $137 million, representing 44% growth. These operating figures support the commercial case, although the September price breach has already ended the published advance thesis. [Company results](https://investors.kestramedical.com/news-releases/news-release-details/kestra-medical-technologies-reports-fourth-quarter-and-fiscal-0).\n\n## Bear Case\n\n- **Price invalidation preceded the catalyst.** The 2026-09-11 close of $22.85 finished below the previously published $24 weekly threshold; the 2026-08-28 reference close had been $25.64.\n- **Growth guidance implies slower expansion.** Management’s 44% fiscal 2027 revenue-growth forecast, issued 2026-07-14, compares with reported fiscal 2026 growth of 59%.\n- **Annual losses continued to widen.** Kestra reported a fiscal 2026 net loss of $131.6 million, versus $113.8 million for fiscal 2025, on 2026-07-14. Higher gross margin had not produced annual profitability. [Company results](https://investors.kestramedical.com/news-releases/news-release-details/kestra-medical-technologies-reports-fourth-quarter-and-fiscal-0).\n\n## Setup & Price Structure\n\nThe supplied adjusted market series records a $22.85 close on 2026-09-11, 19.4% below its $28.35 52-week high, despite a positive three-month price change of 9.6%. Its 14-period relative strength index (RSI) was 18.6. That momentum reading does not establish a reversal; the observable structural event is the weekly breach of $24.\n\nAnalyst attention persisted during the decline. Benzinga’s 2026-09-11 preview reported that BTIG maintained its $32 analyst price target on 2026-09-02 and cited quarterly revenue consensus of $29.01 million. The reiteration and earnings preview document coverage, but this sample is too small to support a retail-crowding claim. No moving-average distance or quantified fund-flow evidence is available here. [Benzinga preview](https://www.benzinga.com/analyst-stock-ratings/price-target/26/09/61733582/kestra-likely-to-report-q1-loss-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call).\n\n## Catalyst Calendar (next 30 days)\n\n*No upcoming dated catalysts on file — the dated entries below have passed.*\n\n## Elapsed catalysts\n\n- **2026-09-14 — Fiscal first-quarter results.** Kestra’s 2026-08-31 announcement confirms publication after the market close and a conference call at 4:30 p.m. Eastern Time. Revenue, prescriptions and updated guidance provide the next operating test; the scheduled report does not reverse the price invalidation already recorded. [Company announcement](https://investors.kestramedical.com/news-releases/news-release-details/kestra-medical-technologies-report-first-quarter-fiscal-2027). *(passed 6d ago)*\n\n## What Would Change Our Mind\n\nThe post-guidance advance has already lost its published structural condition: a weekly close below $24 occurred with the $22.85 close on 2026-09-11. The threshold remains unchanged for the dated record.\n\nA subsequent weekly close above $24, accompanied by a fiscal 2027 revenue-guidance increase above the $137 million announced on 2026-07-14, would supply evidence for a separate recovery thesis. A guidance reduction at the 2026-09-14 report would instead weaken the remaining operating case. Neither outcome would erase the earlier breach.\n\n## Correlation Notes\n\nThis remains a single-name setup. No matched peer-return series or measured sector correlation accompanies the 2026-09-11 price observations, so neither a medtech group explanation for the decline nor a group-led recovery claim is supported. The next company-confirmed event is Kestra’s own 2026-09-14 earnings report.",
  "first_seen": "2026-08-21",
  "last_analyzed": "2026-09-13T02:04:47+00:00",
  "last_synthesized": "2026-09-13",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}